EC Number |
Inhibitors |
Structure |
---|
2.7.1.105 | (2E)-1-(pyridin-4-yl)-3-(quinolin-2-yl)prop-2-en-1-one |
- |
|
2.7.1.105 | (2E)-3-(pyridin-3-yl)-1-(pyridin-4-yl)prop-2-en-1-one |
- |
|
2.7.1.105 | 1-(3-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one |
- |
|
2.7.1.105 | 1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one |
the inhibitor causes a rapid induction of apoptosis in transformed cells, has adequate pharmacokinetic properties, suppresses the glucose uptake and growth of Lewis lung carcinomas in syngeneic mice and yields anti-tumor effects in three human xenograft models of cancer in athymic mice that are comparable to FDA-approved chemotherapeutic agents |
|
2.7.1.105 | 1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one |
- |
|
2.7.1.105 | 2,5-anhydro-D-mannitol 6-phosphate |
- |
|
2.7.1.105 | 2-((5-bromo-6-oxo-1-phenyl-1,6-dihydropyridazin-4-yl)amino)acetamide |
- |
|
2.7.1.105 | 2-(2-bromoacetamido)ethyl phosphate |
an irreversible inhibitor of PFK-2 in several cancer cell lines |
|
2.7.1.105 | 2-(5-bromo-6-oxo-1-phenyl-1,6-dihydropyridazin-4-yl)-1,2,3,4-tetrahydroisoquinoline-5-carbonitrile |
- |
|
2.7.1.105 | 2-hydroxy-4-[(naphthalen-1-ylsulfonyl)amino]benzoic acid |
- |
|